ArcticZymes Technologies - Regulatory Filings 2017

Extended distribution agreement with Rogg Verbandstoffe in Germany

(Tromsø, 18 July 2017) Biotec Pharmacon's ("Biotec", OSE: BIOTEC) subsidiary

Biotec Betaglucans AS has extended the distribution agreement for Woulgan in

Germany with Rogg Verbandstoffe (Rogg) for an additional 12 months with

automatic renewal thereafter

Svein Lien, CEO of Biotec Pharmacon ASA says: -We are very pleased to extend

this agreement, providing our customers with a consistent presence in the German

market. Rogg will continue to promote the benefits of Woulgan to customers in

physician offices and pharmacies and Biotec will support Rogg, by creating

customer demand for Woulgan through its marketing division. Sales to

the physician and pharmacies channel are growing and both parties are encouraged

for the future collaboration in the German market.

Woulgan® is a premium priced product targeting stalled wounds in the

professional wound care market. Clinical experience with Woulgan® demonstrates

significantly improved healing compared to standard care which drives repeated

customer selection.

Rogg is a German company founded in 1970 and is one of Germany's leading

suppliers of wound care products to the health sector. The company is primarily

supplying physician offices and pharmacies, which are important segments for

Woulgan®. Rogg is owned and run by Prof. Dr. Dr Ulrich Hemel, who has a long

track record managing wound care companies.

For additional information,

Svein Lien, CEO, +47 922 89 323, [email protected]

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and

ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel

immunomodulating products, including Woulgan®, a premium priced product in the

advanced wound care market. ArcticZymes develops, produces and markets enzymes

of marine origin used in molecular DNA technologies and diagnostics,

representing growth markets where rapid technological developments are creating

a strong demand for new and improved enzymes.

AI assistant